Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

EOLS vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
EOLS
Evolus, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$416M
5Y Perf.+38.3%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$91.09B
5Y Perf.+368.7%

EOLS vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
EOLS logoEOLS
MCK logoMCK
IndustryDrug Manufacturers - Specialty & GenericMedical - Distribution
Market Cap$416M$91.09B
Revenue (TTM)$301M$397.96B
Net Income (TTM)$-43M$4.34B
Gross Margin65.7%3.4%
Operating Margin-9.6%1.3%
Forward P/E19.1x
Total Debt$155M$7.39B
Cash & Equiv.$54M$5.69B

EOLS vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

EOLS
MCK
StockMay 20May 26Return
Evolus, Inc. (EOLS)100138.3+38.3%
McKesson Corporation (MCK)100468.7+368.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: EOLS vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK leads in 6 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
EOLS
Evolus, Inc.
The Specific-Use Pick

In this particular matchup, EOLS is outpaced on most metrics by others in the set.

Best for: healthcare exposure
MCK
McKesson Corporation
The Income Pick

MCK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 17 yrs, beta 0.04, yield 0.4%
  • Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
  • 351.9% 10Y total return vs EOLS's -45.0%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK16.2% revenue growth vs EOLS's 11.6%
Quality / MarginsMCK logoMCK1.1% margin vs EOLS's -14.4%
Stability / SafetyMCK logoMCKBeta 0.04 vs EOLS's 1.27
DividendsMCK logoMCK0.4% yield; 17-year raise streak; the other pay no meaningful dividend
Momentum (1Y)MCK logoMCK+5.0% vs EOLS's -45.6%
Efficiency (ROA)MCK logoMCK5.3% ROA vs EOLS's -19.4%, ROIC 5.4% vs -44.5%

EOLS vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

EOLSEvolus, Inc.
FY 2025
Product
99.3%$295M
Service
0.7%$2M
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

EOLS vs MCK — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCKLAGGINGEOLS

Income & Cash Flow (Last 12 Months)

MCK leads this category, winning 4 of 6 comparable metrics.

MCK is the larger business by revenue, generating $398.0B annually — 1320.4x EOLS's $301M. MCK is the more profitable business, keeping 1.1% of every revenue dollar as net income compared to EOLS's -14.4%. On growth, MCK holds the edge at +11.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricEOLS logoEOLSEvolus, Inc.MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$301M$398.0B
EBITDAEarnings before interest/tax-$21M$5.8B
Net IncomeAfter-tax profit-$43M$4.3B
Free Cash FlowCash after capex-$41M$10.1B
Gross MarginGross profit ÷ Revenue+65.7%+3.4%
Operating MarginEBIT ÷ Revenue-9.6%+1.3%
Net MarginNet income ÷ Revenue-14.4%+1.1%
FCF MarginFCF ÷ Revenue-13.7%+2.5%
Rev. Growth (YoY)Latest quarter vs prior year+6.2%+11.4%
EPS Growth (YoY)Latest quarter vs prior year+46.7%+38.2%
MCK leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — EOLS and MCK each lead in 1 of 2 comparable metrics.
MetricEOLS logoEOLSEvolus, Inc.MCK logoMCKMcKesson Corporat…
Market CapShares × price$416M$91.1B
Enterprise ValueMkt cap + debt − cash$517M$92.8B
Trailing P/EPrice ÷ TTM EPS-7.90x28.91x
Forward P/EPrice ÷ next-FY EPS est.19.06x
PEG RatioP/E ÷ EPS growth rate0.74x
EV / EBITDAEnterprise value multiple18.53x
Price / SalesMarket cap ÷ Revenue1.40x0.25x
Price / BookPrice ÷ Book value/share
Price / FCFMarket cap ÷ FCF17.43x
Evenly matched — EOLS and MCK each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 7 comparable metrics.

On the Piotroski fundamental quality scale (0–9), MCK scores 6/9 vs EOLS's 3/9, reflecting solid financial health.

MetricEOLS logoEOLSEvolus, Inc.MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity
ROA (TTM)Return on assets-19.4%+5.3%
ROICReturn on invested capital-44.5%+5.4%
ROCEReturn on capital employed-23.5%+30.5%
Piotroski ScoreFundamental quality 0–936
Debt / EquityFinancial leverage
Net DebtTotal debt minus cash$101M$1.7B
Cash & Equiv.Liquid assets$54M$5.7B
Total DebtShort + long-term debt$155M$7.4B
Interest CoverageEBIT ÷ Interest expense-1.92x25.04x
MCK leads this category, winning 5 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

MCK leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $40,840 today (with dividends reinvested), compared to $7,290 for EOLS. Over the past 12 months, MCK leads with a +5.0% total return vs EOLS's -45.6%. The 3-year compound annual growth rate (CAGR) favors MCK at 26.8% vs EOLS's -10.9% — a key indicator of consistent wealth creation.

MetricEOLS logoEOLSEvolus, Inc.MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date-6.0%-9.6%
1-Year ReturnPast 12 months-45.6%+5.0%
3-Year ReturnCumulative with dividends-29.2%+104.0%
5-Year ReturnCumulative with dividends-27.1%+308.4%
10-Year ReturnCumulative with dividends-45.0%+351.9%
CAGR (3Y)Annualised 3-year return-10.9%+26.8%
MCK leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

MCK leads this category, winning 2 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than EOLS's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MCK currently trades 74.4% from its 52-week high vs EOLS's 52.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricEOLS logoEOLSEvolus, Inc.MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5001.27x0.04x
52-Week HighHighest price in past year$12.16$999.00
52-Week LowLowest price in past year$3.86$637.00
% of 52W HighCurrent price vs 52-week peak+52.0%+74.4%
RSI (14)Momentum oscillator 0–10077.625.8
Avg Volume (50D)Average daily shares traded1.1M737K
MCK leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates EOLS as "Buy" and MCK as "Buy". Consensus price targets imply 137.3% upside for EOLS (target: $15) vs 35.3% for MCK (target: $1007). MCK is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.

MetricEOLS logoEOLSEvolus, Inc.MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$15.00$1006.50
# AnalystsCovering analysts1331
Dividend YieldAnnual dividend ÷ price+0.4%
Dividend StreakConsecutive years of raises17
Dividend / ShareAnnual DPS$2.69
Buyback YieldShare repurchases ÷ mkt cap0.0%+3.5%
Insufficient data to determine a leader in this category.
Key Takeaway

MCK leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.

Best OverallMcKesson Corporation (MCK)Leads 4 of 6 categories
Loading custom metrics...

EOLS vs MCK: Frequently Asked Questions

9 questions · data-driven answers · updated daily

01

Is EOLS or MCK a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus 11. 6% for Evolus, Inc. (EOLS). McKesson Corporation (MCK) offers the better valuation at 28. 9x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Evolus, Inc. (EOLS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — EOLS or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +308.

4%, compared to -27. 1% for Evolus, Inc. (EOLS). Over 10 years, the gap is even starker: MCK returned +351. 9% versus EOLS's -45. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — EOLS or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Evolus, Inc. 's 1. 27β — meaning EOLS is approximately 2848% more volatile than MCK relative to the S&P 500.

04

Which is growing faster — EOLS or MCK?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus 11. 6% for Evolus, Inc. (EOLS). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to 1. 2% for Evolus, Inc.. Over a 3-year CAGR, EOLS leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — EOLS or MCK?

McKesson Corporation (MCK) is the more profitable company, earning 0.

9% net margin versus -17. 4% for Evolus, Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus -12. 7% for EOLS. At the gross margin level — before operating expenses — EOLS leads at 64. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is EOLS or MCK more undervalued right now?

Analyst consensus price targets imply the most upside for EOLS: 137.

3% to $15. 00.

07

Which pays a better dividend — EOLS or MCK?

In this comparison, MCK (0.

4% yield) pays a dividend. EOLS does not pay a meaningful dividend and should not be held primarily for income.

08

Is EOLS or MCK better for a retirement portfolio?

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +351. 9% 10Y return). Both have compounded well over 10 years (MCK: +351. 9%, EOLS: -45. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between EOLS and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EOLS is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

EOLS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 39%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform EOLS and MCK on the metrics below

Revenue Growth>
%
(EOLS: 6.2% · MCK: 11.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.